AKOYA BIOSCIENCES ($NASDAQ:AKYA) reported total revenue of USD 23.5 million for the second quarter of its 2023 fiscal year, representing a 31.5% increase from the same period in the previous year. Net income for this quarter was USD -20.8 million, an uptick from the prior year’s -17.5 million.
GoodWhale conducted a thorough analysis of AKOYA BIOSCIENCES‘ wellbeing, taking into account various financial and business aspects. As a result of their evaluation, AKOYA BIOSCIENCES was identified as a high-risk investment according to their Risk Rating. This assessment was based on warnings detected from the company’s income sheet, balance sheet, and cashflow statement. If you would like to take a closer look at these risk warnings and see what GoodWhale’s analysis of AKOYA BIOSCIENCES is, be sure to register on goodwhale.com. Here, you can get a better feel for how your potential investments are doing and make more informed decisions. More…
Risk Rating Analysis
Star Chart Analysis
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Akoya Biosciences. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Akoya Biosciences. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Akoya Biosciences. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Akoya Biosciences are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Akoya Biosciences offers a variety of products and services, including cell culture products, reagents and kits, and services for cell and molecular biology research. Akoya Biosciences has a strong focus on customer service and providing high quality products and services. Akoya Biosciences is a privately held company headquartered in Woburn, Massachusetts, USA. Akoya Biosciences’ main competitors are BibbInstruments AB, Shanghai Model Organisms Center Inc, Abcam PLC.
– BibbInstruments AB ($LTS:0GIA)
Bibb Instruments AB has a market cap of 9.19M as of 2022, a Return on Equity of -18.23%. The company produces and sells medical instruments and equipment. It offers products in the areas of cardiology, ENT, gastroenterology, gynecology, urology, and others.
– Shanghai Model Organisms Center Inc ($SHSE:688265)
Shanghai Model Organisms Center Inc is a biotechnology company that focuses on the research and development of model organisms. The company has a market cap of 3.84B as of 2022 and a ROE of 1.16%. Shanghai Model Organisms Center Inc’s main products are mice and rats for research purposes. The company is headquartered in Shanghai, China.
Abcam PLC is a life sciences company that provides antibodies and other protein tools for scientific research. The company has a market capitalization of $2.91 billion and a return on equity of 2.69%. Abcam’s products are used in a variety of research applications, including cell biology, immunology, and drug development. The company has a strong presence in the life sciences market, with over 1,000 employees in 30 countries.
Investors analyzing Akoya Biosciences may view the company’s second quarter FY2023 earnings with cautious optimism. Total revenue for the quarter saw a healthy increase of 31.5% year-over-year, reaching USD 23.5 million. Overall, Akoya Biosciences appears to be making progress, although profitability remains an ongoing concern.